Clinical trials: Colorectal Tumors
Colorectal Cancer
Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer.
- Trial name
- NCT00047762
- Testing
- Erlotinib (aka Tarceva or OSI-774), Bevacizumab (aka Avastin or Rhu MAb VEGF)
- Where
- 3 sites in United States
- Sponsor
- Genentech, Inc.
Rectal Cancer, Lung Cancer
A Phase I Clinical Trial of Bevacizumab Injection
Recombinant humanized monoclonal antibody injection against human vascular endothelial growth factor (bevacizumab) is Avastin produced by Zhengda Tianqing Pharmaceutical Group Co., Ltd Biological similar drugs.
- Conditions
- Rectal Cancer, Lung Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- NCT05476341
- Testing
- Bevacizumab injection, Bevacizumab injection（Avastin）
- Where
- China
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Cancer
Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer
In this study, patients will receive either pemetrexed plus irinotecan or 5-fluorouracil (5-FU), leucovorin, and irinotecan. The purposes of this study are to determine: How pemetrexed plus irinotecan compares with 5-FU…
- Trial name
- NCT00079872
- Testing
- Pemetrexed
- Where
- 6 sites in Australia, Germany and 3 more
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
Metastatic Colorectal Cancer
Phase II Study of EMB-01 in Recurrent/Metastatic Colorectal Cancer Patients
This study is testing different dosing schedules of EMB-01 in patients with advanced colorectal cancer whose disease has recurrent or progressed on previous treatments.
- Trial name
- NCT07314294
- Testing
- EMB-01 1600 mg administered once weekly throughout the study, EMB-01 1600 mg once weekly for 6 weeks, then every 2 weeks thereafter
- Where
- 2 sites in China
- Volunteers
- 54 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Colorectal Neoplasms
Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS/BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)
The purpose of this study was to assess the preliminary antitumor activity, safety and tolerability of tepotinib in combination with cetuximab in participants with RAS/BRAF wild-type left-sided Metastatic Colorectal Cancer (mCRC)…
- Trial name
- NCT04515394
- Testing
- Tepotinib, Cetuximab
- Where
- 65 sites in United States, Belgium and 6 more
- Volunteers
- 3 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Neoplasms, Advanced Solid Tumors
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JNJ-74699157 in participants with advanced solid tumors harboring a kirsten rat sarcoma virus homolog (KRAS)…
- Conditions
- Neoplasms, Advanced Solid Tumors, Non-small Cell Lung Cancer, Colorectal Cancer
- Trial name
- NCT04006301
- Testing
- JNJ-74699157
- Where
- 7 sites in United States, France
- Volunteers
- 10 people
- Sponsor
- Janssen Research & Development, LLC
Solid Tumor, Non-small Cell Lung Cancer
Phase 1 Study of BPI-442096 in Advanced Solid Tumor Patients
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BPI-442096, a SHP2 inhibitor, in patients with advanced solid tumors.
- Conditions
- Solid Tumor, Non-small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer
- Trial name
- NCT05369312
- Testing
- BPI-442096
- Where
- 5 sites in China
- Volunteers
- 230 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Neoplasms
Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer
Determine the safety, tolerability, pharmacokinetics, maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of VIP152 (BAY 1251152) as monotherapy or in combination in patients with solid tumors and aggressive…
- Trial name
- NCT02635672
- Testing
- VIP152 (BAY 1251152), VIP152 (BAY 1251152) 30 mg, Keytruda
- Where
- 16 sites in United States, Chile and 1 more
- Volunteers
- 110 people
- Sponsor
- Vincerx Pharma, Inc.
Metastatic Colorectal Cancer
Real World Multicenter National Study to Evaluate the Effectiveness and Safety of Biosimilar Bevacizumab Elovie
Colorectal cancer is one of the most common tumors and is the second most prevalent cause of cancer death, leading to almost 1 million deaths per year.Elovie is a bevacizumab biosimilar medicine marketed by Libbs Farmacêutica…
- Trial name
- NCT06808685
- Where
- 14 sites in Brazil
- Volunteers
- 133 people
- Sponsor
- Libbs Farmacêutica LTDA
Colorectal Cancer Screening
Colorectal Cancer Screening Validation Study
The purpose of this study is to evaluate the gene expression patterns from colorectal mucosal cells collected through the use of a standard anoscope and cytology brush.
- Trial name
- CRC screening (NCT00720993)
- Where
- United States
- Volunteers
- 165 people, healthy volunteers welcome
- Sponsor
- IntelliGeneScan, Inc.
Metastatic Colorectal Cancer
A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer
This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.
- Trial name
- NCT05130021
- Testing
- MAX-40279-01, regorafenib
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Maxinovel Pty., Ltd.
Rectal Cancer
TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer
The purpose of this study is to determine if the addition of TNFerade™ to pre-operative chemoradiotherapy increases the number of pathologic complete responses when compared to pre-operative chemoradiotherapy alone as assessed…
- Trial name
- NCT00137878
- Testing
- TNFerade™
- Where
- United States
- Sponsor
- GenVec
Colorectal Cancer (CRC), Gastric Cancer
A Study of SC-007 in Subjects With Advanced Cancer
This is a multicenter, open-label, Phase 1 study in participants with colorectal cancer (CRC) or gastric cancer to study the safety and tolerability of SC-007 and consists of Part A (dose regimen finding) in participants with CRC…
- Trial name
- NCT03253185
- Testing
- SC-007
- Where
- 7 sites in United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- AbbVie
Metastatic Colorectal Cancer, Colon Cancer
Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer
The goal of this clinical study is to determine the dosing and safety of labetuzumab govitecan (formerly known as IMMU-130; hMN-14-SN38, antibody-drug conjugate) in participants with colorectal cancer.
- Conditions
- Metastatic Colorectal Cancer, Colon Cancer, Rectal Cancer
- Trial name
- NCT01605318
- Testing
- Labetuzumab Govitecan (LG)
- Where
- 7 sites in United States
- Volunteers
- 92 people
- Sponsor
- Gilead Sciences
HNSCC, Melanoma
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
The subject of this study is the adoptive transfer of selected autologous tumor infiltrating lymphocytes (TIL) after in vitro expansion for the treatment of solid tumor malignancies.
- Conditions
- HNSCC, Melanoma, Gynecologic Cancer, Colorectal Cancer
- Trial name
- ACT (NCT05902520)
- Testing
- DP CD8 TIL, DP CD8 TIL KD, Low dose IL-2
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- AgonOx, Inc.
Squamous Cell Carcinoma of the Head and Neck, Melanoma
SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas
This is a Phase 1 first in human, open label, multi-center, dose escalation and dose expansion study to evaluate the safety, tolerability, PK, anti-tumor activity and pharmacodynamic effects of SL-279252 in subjects with advanced…
- Conditions
- Squamous Cell Carcinoma of the Head and Neck, Melanoma, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT03894618
- Testing
- SL-279252
- Where
- 5 sites in United States, Belgium and 2 more
- Volunteers
- 49 people
- Sponsor
- Shattuck Labs, Inc.
Solid Tumors
Cardiac Safety Assessment Study of Picoplatin in Solid Tumors
The purpose of this study is to investigate what effects, if any, picoplatin has on the heart rhythm.
- Trial name
- NCT00710697
- Testing
- Picoplatin
- Where
- 7 sites in United States
- Volunteers
- 40 people
- Sponsor
- Poniard Pharmaceuticals
Colorectal Cancer, Colorectal Carcinoma
A Study of Irinotecan Plus Cetuximab With or Without Enzastaurin in Participants With Colorectal Cancer
To see how well enzastaurin in combination with irinotecan and cetuximab works versus irinotecan and cetuximab in participants who have progressed within 3 months.
- Conditions
- Colorectal Cancer, Colorectal Carcinoma, Colorectal Tumor
- Trial name
- NCT00437268
- Testing
- enzastaurin, irinotecan, cetuximab
- Where
- 20 sites in United States
- Volunteers
- 26 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.